| Market Capitalization (Millions $) |
- |
| Shares
Outstanding (Millions) |
145 |
| Employees |
461 |
| Revenues (TTM) (Millions $) |
133 |
| Net Income (TTM) (Millions $) |
-252 |
| Cash Flow (TTM) (Millions $) |
-114 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Clovis Oncology Inc. is a biopharmaceutical company that is focused on developing innovative anti-cancer treatments. The company was founded in 2009 and is headquartered in Boulder, Colorado. Its stock is traded on the NASDAQ global market under the ticker symbol CLVS.
Clovis Oncology is engaged in the research, development, and commercialization of anti-cancer treatments that target specific genetic mutations that are found in certain forms of cancer. The company's flagship product is Rubraca (rucaparib), an oral, small-molecule inhibitor of poly (ADP-ribose) polymerase (PARP) that is approved in the United States and other countries for the treatment of recurrent ovarian cancer.
Clovis Oncology's pipeline includes several other promising products, including LUCA-19, a monoclonal antibody that targets the protein CD19, which is expressed on the surface of certain blood cancers. Another promising product is FAP-2286, a small molecule drug that targets fibroblast activation protein (FAP), a protein that is found in the stroma of many solid tumors.
The company is led by a management team with deep experience in the biopharmaceutical industry. It has partnerships and collaboration agreements with several other biotechnology and pharmaceutical companies, including Pfizer and Bristol-Myers Squibb.
Clovis Oncology is committed to creating innovative treatments for cancer patients, and its cutting-edge research and development programs have the potential to change the way cancer is treated in the future. Despite setbacks in clinical trials, the company continues to push forward and explore new avenues for cancer treatment.
Company Address: 5500 Flatiron Parkway, Suite 100 Boulder 80301 CO
Company Phone Number: 625-5000 Stock Exchange / Ticker: NASDAQ CLVS
|
%
6.59%